• Molecular NameCyclopentolate
  • SynonymCiclopentolato [INN-Spanish]; Cyclopentoiate; Cyclopentolate HCL; Cyclopentolatum [INN-Latin]; Cyclopentylate; Diopentolate
  • Weight291.391
  • Drugbank_IDDB00979
  • ACS_NO512-15-2
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.4
  • pka7.9
  • LogD (pH=7, predicted)1.22
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.98
  • LogSw (predicted, AB/LogsW2.0)2.17
  • Sw (mg/ml) (predicted, ACD/Labs)1.88
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds7
  • TPSA49.77
  • StatusFDA approved
  • AdministrationTopic
  • PharmacologyA mydriatic and cycloplegic agent commonly used during pediatric eye examinations.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmCyclopentolate is metabolized by plasma pseudocholinesterase. The main metabolites are hydroxycyclopentylphenylacetic acid and N,N-dimethyl-ethanolamine.
  • Half lifeElimination, 111 min.
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include tachycardia, dizziness, dry mouth, behavioral disturbances, uncoordination and drowsiness.
  • LD50 (rat)4000 mg/kg
  • LD50 (mouse)960 mg/kg